Daniel R. Gomez
Expertise in
12
conditions

Dr. Daniel R. Gomez

Radiation Oncology
Memorial Sloan Kettering Cancer Center
1275 York Ave, 
New York, NY 
Accepting New Patients
Offers Telehealth
Expertise in
12
conditions
Memorial Sloan Kettering Cancer Center
1275 York Ave, 
New York, NY 

Overview

Daniel Gomez is a Radiation Oncologist practicing medicine in New York, New York.

Dr. Gomez is highly rated in 12 conditions, according to our data. His clinical expertise encompasses Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Small Cell Lung Cancer (SCLC), and Mesothelioma.

He is actively involved in clinical research, co-authoring 336 peer reviewed articles and participating in 6 clinical trials. Dr. Gomez is currently accepting new patients.

Specialties

Radiation Oncology

Licenses

Radiology in TX

Hospital Affiliations

Nyu Langone Hospitals

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
EmblemHealth
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE PART D
Health First
  • HMO
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 5 Less Insurance Carriers -

Locations

Memorial Sloan Kettering Cancer Center
1275 York Ave, New York, NY 10065

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

Phase II Toxicity Study of Pleurectomy/Decortication, (Neo) Adjuvant Chemotherapy and Intensity Modulated Radiation Therapy to the Pleura in Patients With Locally Advanced Malignant Pleural Mesothelioma
Phase II Toxicity Study of Pleurectomy/Decortication, (Neo) Adjuvant Chemotherapy and Intensity Modulated Radiation Therapy to the Pleura in Patients With Locally Advanced Malignant Pleural Mesothelioma
Enrollment Status: Active_not_recruiting
Publish Date: August 11, 2026
Intervention Type: Procedure, Radiation, Drug
Study Drug: Pemetrexed+Cisplatin or carboplatin
Study Phase: Phase 2
Maintenance Systemic Therapy Versus Local Consolidative Therapy (LCT) Plus Maintenance Systemic Therapy for Limited Metastatic Non-Small Cell Lung Cancer (NSCLC): A Randomized Phase II/III Trial
Maintenance Systemic Therapy Versus Local Consolidative Therapy (LCT) Plus Maintenance Systemic Therapy for Limited Metastatic Non-Small Cell Lung Cancer (NSCLC): A Randomized Phase II/III Trial
Enrollment Status: Active_not_recruiting
Publish Date: June 08, 2026
Intervention Type: Radiation, Drug
Study Drugs: Docetaxel, Gemcitabine, Pemetrexed Disodium, Erlotinib Hydrochloride, Pembrolizumab
Study Phase: Phase 2
Phase I Trial of Adjuvant Pembrolizumab After Radiation Therapy for Lung-Intact Malignant Pleural Mesothelioma
Phase I Trial of Adjuvant Pembrolizumab After Radiation Therapy for Lung-Intact Malignant Pleural Mesothelioma
Enrollment Status: Completed
Publish Date: May 27, 2026
Intervention Type: Radiation, Other, Biological
Study Drug: Pembrolizumab
Study Phase: Phase 1
Randomized Phase II Trial of Osimertinib With or Without Local Consolidation Therapy (LCT) for Patients With EGFR-Mutant Metastatic NSCLC (NORTHSTAR)
Randomized Phase II Trial of Osimertinib With or Without Local Consolidation Therapy (LCT) for Patients With EGFR-Mutant Metastatic NSCLC (NORTHSTAR)
Enrollment Status: Active_not_recruiting
Publish Date: April 06, 2026
Intervention Type: Drug, Radiation, Procedure
Study Drug: Osimertinib
Study Phase: Phase 2
Phase II Double-Blind, Randomized, Placebo Controlled Study to Evaluate the Efficacy and Safety of Nintedanib (BIBF 1120) + Prednisone Taper in Patients With Radiation Pneumonitis
Phase II Double-Blind, Randomized, Placebo Controlled Study to Evaluate the Efficacy and Safety of Nintedanib (BIBF 1120) + Prednisone Taper in Patients With Radiation Pneumonitis
Enrollment Status: Completed
Publish Date: April 16, 2025
Intervention Type: Drug, Other
Study Drugs: Nintedanib, Prednisone
Study Phase: Phase 2
A Randomized Phase II Study Assessing the Efficacy of Local Consolidative Therapy for Non-Small Cell Lung Cancer Patients With Induced Oligometastatic Disease
A Randomized Phase II Study Assessing the Efficacy of Local Consolidative Therapy for Non-Small Cell Lung Cancer Patients With Induced Oligometastatic Disease
Enrollment Status: Completed
Publish Date: October 24, 2024
Intervention Type: Other, Procedure, Radiation
Study Phase: Phase 2
View 5 Less Clinical Trials

336 Total Publications

Durvalumab With Radiation Therapy in Patients With Inoperable Locally Advanced Non-Small Cell Lung Cancer Ineligible for Concurrent Chemoradiotherapy (DART).
Durvalumab With Radiation Therapy in Patients With Inoperable Locally Advanced Non-Small Cell Lung Cancer Ineligible for Concurrent Chemoradiotherapy (DART).
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: July 16, 2026
Similar Doctors
Expertise in
17
conditions
Dr. Andreas Rimner
Radiation Oncology
Expertise in
17
conditions
Dr. Andreas Rimner
Radiation Oncology
Referral may be required

Memorial Sloan Kettering Cancer Center

1275 York Ave, 
New York, NY 
 (0.1 miles away)
212-639-2000
Languages Spoken:
English

Andreas Rimner is a Radiation Oncologist practicing medicine in New York, New York. Dr. Rimner is highly rated in 17 conditions, according to our data. His clinical expertise encompasses Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Mesothelioma, Tissue Biopsy, and Thymectomy.

Expertise in
54
conditions
Dr. Kaled M. Alektiar
Radiation Oncology
Expertise in
54
conditions
Dr. Kaled M. Alektiar
Radiation Oncology
Referral may be required

Memorial Sloan Kettering Cancer Center

1275 York Ave, 
New York, NY 
 (0.1 miles away)
646-582-9491
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Kaled Alektiar is a Radiation Oncologist practicing medicine in New York, New York. Dr. Alektiar is highly rated in 54 conditions, according to our data. His clinical expertise encompasses Endometrial Cancer, Adult Soft Tissue Sarcoma, Fibrosarcoma, Cervical Cancer, and Lymphadenectomy. Dr. Alektiar is currently accepting new patients.

Expertise in
17
conditions
Dr. Joachim Yahalom
Radiation Oncology
Expertise in
17
conditions
Dr. Joachim Yahalom
Radiation Oncology
Referral may be required

Memorial Sloan Kettering Cancer Center

1275 York Ave, 
New York, NY 
 (0.1 miles away)
929-459-8263
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Joachim Yahalom is a Radiation Oncologist practicing medicine in New York, New York. Dr. Yahalom is highly rated in 17 conditions, according to our data. His clinical expertise encompasses Hodgkin Lymphoma, Follicular Lymphoma, Marginal Zone Lymphoma (MZL), Plasmacytoma, and Tissue Biopsy. Dr. Yahalom is currently accepting new patients.

Frequently Asked Questions about Dr. Daniel R. Gomez

How do I make an appointment with Dr. Daniel R. Gomez?

You can book an appointment with Dr. Daniel R. Gomez by calling their office at 315-275-7348. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Daniel R. Gomez a top-rated expert for Lung Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Daniel R. Gomez is classified as an Elite expert for Lung Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Daniel R. Gomez specialize in?

While Dr. Daniel R. Gomez is a Radiation Oncology, they have specific expertise in Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), and Small Cell Lung Cancer (SCLC). MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Radiation Oncology.

Does Dr. Daniel R. Gomez participate in research or clinical trials?

Yes. Dr. Daniel R. Gomez has published 336 articles and abstracts on conditions like Lung Cancer. You can view a list of Dr. Daniel R. Gomez's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Daniel R. Gomez accept my insurance?

Dr. Daniel R. Gomez accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 315-275-7348 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Gomez's expertise for a condition
ConditionClose
View All 8 Distinguished Conditions
View All 37 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile